
AbstractObjectivesComplete deficiency of alternative pathway (AP) complement factors, explained by homozygous mutations, is a well‐known risk factor for invasive bacterial infections; however, this is less obvious for heterozygous mutations. We describe two siblings with a heterozygous NM_001928.3(CFD):c.125C>A p.(Ser42*) mutation in the complement factor D (fD) gene having a history of recurrent bacterial infections. We determined the effect of heterozygous fD deficiency on AP complement activity.MethodsWe determined the effect of fD levels on complement activation as measured by AP activity, complement C3 binding to the bacterial surface of Neisseria meningitidis (Nm), Streptococcus pneumoniae (Sp) and non‐typeable Haemophilus influenzae (NTHi), and complement‐mediated killing of Nm and NTHi. In addition, we measured the effect of vaccination of complement C3 binding to the bacterial surface and killing of Nm.ResultsReconstitution of fD‐deficient serum with fD increased AP activity in a dose‐ and time‐dependent way. Reconstitution of patient serum with fD to normal levels increased complement C3 binding to Sp, Nm and NTHi, as well as complement‐mediated killing of Nm and NTHi. Vaccination increased complement C3 binding and resulted in complete killing of Nm without fD reconstitution.ConclusionWe conclude that low fD serum levels (< 0.5 μg mL−1) lead to a reduced speed of complement activation, which results in diminished bacterial killing, consistent with recurrent bacterial infections observed in our index patients. Specific antibodies induced by vaccination are able to overcome the diminished bacterial killing capacity in patients with low fD levels.
Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Original Articles, RC581-607, vaccination, infection, factor D, Radboudumc 2: Cancer development and immune defence RIHS: Radboud Institute for Health Sciences, Laboratory Medicine - Radboud University Medical Center, haplodeficiency, Human Genetics - Radboud University Medical Center, complement, Internal Medicine - Radboud University Medical Center, Paediatrics - Radboud University Medical Center, Radboudumc 5: Inflammatory diseases RIMLS: Radboud Institute for Molecular Life Sciences, Immunologic diseases. Allergy, immunodeficiency
Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Original Articles, RC581-607, vaccination, infection, factor D, Radboudumc 2: Cancer development and immune defence RIHS: Radboud Institute for Health Sciences, Laboratory Medicine - Radboud University Medical Center, haplodeficiency, Human Genetics - Radboud University Medical Center, complement, Internal Medicine - Radboud University Medical Center, Paediatrics - Radboud University Medical Center, Radboudumc 5: Inflammatory diseases RIMLS: Radboud Institute for Molecular Life Sciences, Immunologic diseases. Allergy, immunodeficiency
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 7 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
